General anaesthesia GA was performed based on our previous optimization [17, 18], in which ketamine (75 mg/kg) intraperitoneally or 3% sevoflurane 2 h inhalation daily for three consecutive days can induce neurotoxicity and cognitive impairments
Clinical trials show average weight loss of 1015% body weight over 40 weeks with minimal dietary intervention
Actions of pituitary hormones beyond traditional targets
Important Safety Information Do not use AOD-9604 if you: Have a known allergy to growth hormone fragments or any component of the formulation Have been diagnosed with active cancer or have a history of malignancy (use only under medical supervision) Are pregnant or breastfeeding (safety data is lacking) Have severe uncontrolled diabetes or metabolic disorders without medical supervision Common side effects may include: Injection site reactions, mild headaches, temporary fatigue, or slight dizziness during initial use
Nyberg J, Jacobsson C, Anderson MF, Eriksson PS
These therapies, initially designed for type 2 diabetes, have demonstrated significant weight loss benefits, leading to their expanded use in obesity management